Biogenic nanosilver inhibits Mycobacteria using nitrate reductase assay. (23rd August 2019)

• Record Type: Journal Article
• Authors: Bello, Adebayo J.; Adams, Luqman A.; Onyejepu, Nneka N.; Igbinehi, Justice I.; Igbari, Omoboyede F.; Okpuzor, Joy
• Is Part Of: International journal of nano and biomaterials. Volume 8:Number 2(2019)
• Page Start: 129
• Page End: 145
• Publication Date: 2019-08-23
• Subjects: Mycobacteria -- tuberculosis -- nanosilver -- biosynthesis -- Moringa oleifera -- Allium cepa -- nitrate reductase assay -- NRA -- MO-AgNPs -- AC-AgNPs -- minimum inhibitory complex; Nanostructured materials -- Periodicals; Nanotechnology -- Periodicals; Biomedical materials -- Periodicals; 620.505
• Languages: English
• ISSNs: 1752-8933

Abstract

Nanosilver was synthesised by bioreduction using aqueous extracts of Moringa oleifera (MO-AgNPs) leaf and Allium cepa bulb (AC-AgNPs) as reducing and capping agents. The nanosilver was characterised with UV/vis, FT-IR, and SEM-EDX. Microbiological activity on five Mycobacteria strains: ATCC 35882, ATCC 25177, Mycobacterium other than tuberculosis (MOTT), Mycobacterium fortuitum and multi drug resistance M. tuberculosis (MDR-MTB) was investigated using nitrate reductase assay (NRA). Results obtained for UV/vis gave absorption maxima at 430 nm for MO-AgNPs and 440 nm for AC-AgNPs. FT-IR showed functional groups associated with the biomolecular capping agents. SEM showed the nanosilver formed aggregates spherical and/or in oval shape with smooth surface. EDX spectra exhibited the presence of elemental silver. Minimum inhibitory concentration (MIC) study for both nanosilver against Mycobacteria indicated a higher inhibitory activity for MO-AgNPs over the AC-AgNPs. Herein, we have reported the first biosynthesised nanosilver activity against Mycobacteria using NRA. Nanosilver may therefore be developed as nanoaerosol for targeted and effective treatment of Mycobacteria infections.